Pradeep Nagaraju, MD
Urogynecology and Reconstructive Pelvic Surgery · Royal Oak, MINPI 1285615583
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 142 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 17.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,123 and has fallen 50.0% since, to $561 in 2025.
Across 142 payments — averaging $32.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$815
- Boston Scientific$490
- AbbVie$487
- Ferring Pharmaceuticals Inc.$430
- Caldera Medical, Inc$361
- Axonics, Inc.$259
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,63899%
- Education$291%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 10 | $815 |
| Boston Scientific | 5 | $490 |
| AbbVie(2 entities) | 30 | $487 |
| Ferring Pharmaceuticals Inc. | 7 | $430 |
| Caldera Medical, Inc | 3 | $361 |
| Axonics, Inc. | 4 | $259 |
| Sumitomo Pharma America, Inc. | 12 | $228 |
| Teleflex LLC | 2 | $158 |
| Neotract Inc. | 2 | $157 |
| Astellas Pharma US Inc | 8 | $134 |
| Antares Pharma, Inc. | 6 | $115 |
| Coloplast | 6 | $92 |
| Laborie Medical Technologies Corp. | 1 | $90 |
| Intuitive Surgical | 1 | $87 |
| Merck | 3 | $86 |
| Olympus America Inc. | 4 | $84 |
| Urovant Sciences Inc | 6 | $83 |
| Tolmar, Inc. | 4 | $67 |
| Blue Earth Diagnostics | 4 | $61 |
| Johnson & Johnson | 4 | $59 |
| Pfizer | 3 | $38 |
| Bayer | 3 | $38 |
| Endo USA, Inc. | 2 | $36 |
| Urogen Pharma, Inc. | 2 | $32 |
| 180 Medical, Inc. | 2 | $30 |
| Myriad Genetic Laboratories, Inc. | 2 | $30 |
| Palette Life Sciences, Inc. | 1 | $22 |
| Sun Pharmaceutical Industries Inc. | 1 | $21 |
| Amgen | 1 | $20 |
| Halozyme Inc | 1 | $20 |
| Clarus Therapeutics Inc. | 1 | $19 |
| Tempus AI, Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$598
- FIRMAGON$367
- Desara$361
- UroLift$275
- UPSYLON$266
- GENERAL FEMALE SUI$170
- INTERSTIM ICON$153
- Axonics$126
How this compares
$4,667 in reported general payments places this provider in the 65th percentile of 33 urogynecology and reconstructive pelvic surgery providers in Michigan.
See all urogynecology and reconstructive pelvic surgery providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 113 | $110,087 |
| GemtesaVibegron | 116 | $95,565 |
| Mirabegron ErMirabegron | 33 | $24,515 |
| Tamsulosin Hcl | 1,133 | $21,297 |
| Trospium Chloride | 138 | $13,116 |
| Methenamine Hippurate | 182 | $12,586 |
| Finasteride | 491 | $9,494 |
| Solifenacin Succinate | 215 | $9,427 |
| Estradiol | 129 | $9,017 |
| Tolterodine Tartrate ErTolterodine Tartrate | 59 | $7,211 |
| Silodosin | 58 | $6,120 |
| Oxybutynin Chloride ErOxybutynin Chloride | 165 | $4,978 |
| NitrofurantoinNitrofurantoin Macrocrystal | 89 | $4,564 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 166 | $4,428 |
| Potassium Citrate ErPotassium Citrate | 32 | $4,082 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $134 | $110,087113 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $228 | $95,565116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 33 urogynecology and reconstructive pelvic surgery providers in Michigan.
Other urogynecology and reconstructive pelvic surgery in Royal Oak
- Melissa FischerRoyal Oak$11K
- Gabrielle RohrerRoyal Oak$5K
- Jaber SaadRoyal Oak$2K
- Jannah ThompsonNorton Shores$474K
- Jason BennettGrand Rapids$68K
- Priyanka GuptaAnn Arbor$39K
- Jason CruffDearborn$12K
- John DelanceyAnn Arbor$11K
- Anne CameronBrighton$7K
- Ali LuckWest Bloomfield$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.